Back to results
US 2021/0332109 A1Published application
Anti-varicella-zoster virus antibody, immunological measurement method, and immunological measurement device
AssigneesTanaka Kikinzoku Kogyo K.K., Tomiyama Laboratories Inc.
InventorsHisahiko IWAMOTO, Keita SUZUKI, Tetsuo TOMIYAMA
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a means for rapidly diagnosing infection with VZV. The present invention relates to an antibody against VZV gE or an antibody fragment thereof, and an immunological measurement method and an immunological measurement device using the antibody or the antibody fragment thereof, etc.
Claims20
An antibody against glycoprotein E of varicella-zoster virus (hereinafter varicella-zoster virus is abbreviated as VZV, and glycoprotein E of varicella-zoster virus is abbreviated as VZV gE) or an antibody fragment thereof, wherein the antibody is any one of the following antibodies (1a) to (1c) and (2a) to (2c):
- (1a) an antibody in which the amino acid sequences of complementarity determining regions (hereinafter abbreviated as CDRs) 1 to 3 of a heavy chain variable region (hereinafter abbreviated as VH) contain the amino acid sequences represented by SEQ ID NOS:
- 8, 9, and 10, respectively, and the amino acid sequences of CDRs 1 to 3 of a light chain variable region (hereinafter abbreviated as VL) contain the amino acid sequences represented by SEQ ID NOS:
- 11, 12, and 13, respectively;
- (1b) an antibody which contains an amino acid sequence, in which one to three amino acid residues are deleted, substituted, added, or inserted in at least any one of the amino acid sequences of CDRs 1 to 3 of VH and CDRs 1 to 3 of VL of the antibody (1a), and has an antigen-binding activity equivalent to that of the antibody (1a);
- (1c) an antibody, in which the amino acid sequences of CDRs 1 to 3 of VH of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 8, 9, and 10, respectively, and the amino acid sequences of CDRs 1 to 3 of VL of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 11, 12, and 13, respectively, and which has an antigen-binding activity equivalent to that of the antibody (1a);
- (2a) an antibody in which the amino acid sequences of CDRs 1 to 3 of VH of the antibody contain the amino acid sequences represented by SEQ ID NOS:
- 14, 15, and 16, respectively, and the amino acid sequences of CDRs 1 to 3 of VL of the antibody contain the amino acid sequences represented by SEQ ID NOS:
- 17, 18, and 19, respectively;
- (2b) an antibody which contains an amino acid sequence, in which one to three amino acid residues are deleted, substituted, added, or inserted in at least any one of the amino acid sequences of CDRs 1 to 3 of VH and CDRs 1 to 3 of VL of the antibody (2a), and has an antigen-binding activity equivalent to that of the antibody (2a);
- and
- (2c) an antibody, in which the amino acid sequences of CDRs 1 to 3 of VH of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 14, 15, and 16, respectively, and CDRs 1 to 3 of VL of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 17, 18, and 19, respectively, and which has an antigen-binding activity equivalent to that of the antibody (2a).
12 more elements
An antibody against VZV gE or an antibody fragment thereof, which specifically recognizes the amino acid sequence at positions 48 to 88 in the amino acid sequence represented by SEQ ID NO:
- 1, and does not specifically recognize the amino acid sequence at positions 48 to 67, the amino acid sequence at positions 54 to 72, the amino acid sequence at positions 62 to 81, and the amino acid sequence at positions 69 to 88 in the amino acid sequence represented by SEQ ID NO:
- 1.
An immunological measurement method, which comprises using any one of the following antibodies (1a) to (1c) or an antibody fragment thereof and any one of the following antibodies (2a) to (2c) or an antibody fragment thereof:
- (1a) an antibody in which the amino acid sequences of CDRs 1 to 3 of VH contain the amino acid sequences represented by SEQ ID NOS:
- 8, 9, and 10, respectively, and the amino acid sequences of CDRs 1 to 3 of VL contain the amino acid sequences represented by SEQ ID NOS:
- 11, 12, and 13, respectively;
- (1b) an antibody which contains an amino acid sequence, in which one to three amino acid residues are deleted, substituted, added, or inserted in at least any one of the amino acid sequences of CDRs 1 to 3 of VH and CDRs 1 to 3 of VL of the antibody (1a), and has an antigen-binding activity equivalent to that of the antibody (1a);
- (1c) an antibody, in which the amino acid sequences of CDRs 1 to 3 of VH of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 8, 9, and 10, respectively, and the amino acid sequences of CDRs 1 to 3 of VL of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 11, 12, and 13, respectively, and which has an antigen-binding activity equivalent to that of the antibody (1a);
- (2a) an antibody in which the amino acid sequences of CDRs 1 to 3 of VH of the antibody contain the amino acid sequences represented by SEQ ID NOS:
- 14, 15, and 16, respectively, and the amino acid sequences of CDRs 1 to 3 of VL of the antibody contain the amino acid sequences represented by SEQ ID NOS:
- 17, 18, and 19, respectively;
- (2b) an antibody which contains an amino acid sequence, in which one to three amino acid residues are deleted, substituted, added, or inserted in at least any one of the amino acid sequences of CDRs 1 to 3 of VH and CDRs 1 to 3 of VL of the antibody (2a), and has an antigen-binding activity equivalent to that of the antibody (2a);
- and
- (2c) an antibody, in which the amino acid sequences of CDRs 1 to 3 of VH of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 14, 15, and 16, respectively, and the amino acid sequences of CDRs 1 to 3 of VL of the antibody contain amino acid sequences having 80% or more homology with the amino acid sequences represented by SEQ ID NOS:
- 17, 18, and 19, respectively, and which has an antigen-binding activity equivalent to that of the antibody (2a).
12 more elements
Dependencies are inferred from the claim text.